CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 96 enrolled
Drug / intervention
Placebo +5 moredrug
Likely dose
SUN101 3 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02038829
NCT02038829Phase 2Completed
CompareCT.gov

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)

Sunovion Respiratory Development Inc.·interventional·Posted Jan 17, 2014·Updated Apr 10, 2018

In Brief

A Phase 2 clinical trial evaluating Placebo, SUN101 3 mcg, and 4 other interventions for COPD. Completed, enrolled 96 participants across 10 sites.

Detailed Summary

Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 17, 2014
Enrollment StartJan 1, 2014
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.5 years ago

Interventions

Placebodrug

Placebo

SUN101 3 mcgdrug

SUN-101 3 mcg bid

SUN-101 6.25 mcgdrug

SUN-101 6.25 mcg bid

SUN-101 12.5 mcgdrug

SUN-101 12.5 mcg bid

SUN-101 50 mcgdrug

SUN-101 50 mcg bid

Aclidiniumdrug

Aclidinium 400 mcg bid